Author’s response to reviews

Title: Glutamate metabotropic receptor 4 (GRM4) inhibits cell proliferation, migration and invasion in breast cancer and is regulated by miR-328-3P and miR-370-3P

Authors:

Linhai Li (mature303@126.com)
Bin Xiao (xiaobin2518@163.com)
Daxiang Chen (1101072690@qq.com)
Jianfeng Hang (hyhy160@163.com)
Weiyun Zhang (1261349825@qq.com)
Zhenzhan Kuang (864156363@qq.com)
Quan Zhou (springzhou@yeah.net)
Yang Liao (13889908240@163.com)
Zhaohui Sun (zhaohui3@126.com)

Version: 1 Date: 16 Jan 2019

Author’s response to reviews:

1 - Any manuscript submitted to a BioMed Central journal must be original and the manuscript, or substantial parts of it, must not be under consideration by any other journal. We note that the current submission contains textual overlap with other previously published works. Please re-write these sentences and phrases in your own words to ensure no overlap. If there is overlap in the Methods section, please ensure that you summarize the methods and cite the source.
Response: We have re-written the overlap sections.

2 - Please include email addresses for all authors on the title page.
Response: We have included email addresses for all authors on the title page.

3 - Please order the ‘Declaration’ section, including all sub sections, as follows with a heading:

Declarations

Ethics approval and consent to participate
Consent for publication
Availability of data and material
Competing interests
Funding
Authors' contributions
Acknowledgements
Authors' information (optional)

Response: We have re-ordered the ‘Declaration’ section.

4 - In the Funding section of the Declarations please indicate the role of the funding body in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript. If no specific funding was received for this study, please clearly indicate this in the Funding section.
Response: We have indicated the role of the funding body in the design of the study and collection, analysis, and interpretation of data.

5 - Please include a Figure Legends heading.
Response: We have included a Figure Legends heading